Click on image to view larger version.
FIGURE 2. (A) Biodistribution was determined through the use of C57BL/6 mice with syngeneic grafted B16-F1 melanoma tumors. These mice received tail vein injections of 5 x 1012 virions of bio-MSH2.0 phage. Four hours later, mice received tail vein injections of 1.85 MBq of 111In-SA. Mice were sacrificed at 0.5, 2, 4, 6, and 24 h after injection, and their organs were harvested for counting. (B) Tumor-to-muscle ratios and tumor-to-blood ratios for both bio-MSH2.0 phage and bio-WT phage were compared. C57BL/6 mice bearing B16-F1 tumors received tail injections of 5 x 1012 virions of bio-WT phage and, 4 h later, 1.85 MBq of 111In-SA. (C) At 24 h after injection of 111In-SA, levels of accumulation of radioactivity within tumor were compared for bio-MSH2.0 phage and bio-WT phage. (D) C57BL/6 mice with syngeneic grafted B16-F1 melanoma tumors received tail vein injections of either 5 x 1012 virions of bio-MSH2.0 phage or 5 x 1012 virions of bio-MSH2.0 phage mixed with 100 µg of NDP. Four hours later, mice received tail vein injections of 1.85 MBq of 111In-SA. Mice were sacrificed at 2 h after injection, and levels of accumulation of radiolabel within tumor were compared for both phage. *P = 0.001; **P = 0.002; ***P = 0.003.
